Ann gained a PhD from Cambridge University studying inflammatory responses in vascular endothelial cells at the Babraham Institute. After training in microvascular biology with Professor Judah Folkman in Boston, she began her life-long interests in high endothelial venule (HEV) blood vessels and T-cell trafficking as a postdoctoral fellow with Professor Bill Ford at the University of Manchester. Ann gained an MRC Senior Fellowship in Manchester and moved to a PI position at the MRC National Institute for Medical Research in London where she began working on L-selectin/CD62L. Ann moved to Cardiff University as Reader and was awarded a personal chair as Professor of Cellular Immunity and Immunotherapy.
The Ager lab studies how T lymphocytes move around the body to protect against infection, control cancer progression and contribute to neurodegeneration such as in Alzheimer's disease. A major focus has been the regulation of L-selectin/CD62L expression by T lymphocytes and its impact on physiological and pathological T-cell recruitment from the bloodstream into tissues via specialised high endothelial venule (HEV) and inflamed blood vessels. Recent studies have revealed an essential role for L-selectin in the recruitment of killer T cells into flu-infected lungs for virus clearance (http://www.bbc.co.uk/news/uk-wales-south-east-wales-35373730). Current studies are testing whether manipulating L-selectin on cancer-killing T lymphocytes, such as CAR-T cells, increases their ability to seek out and destroy solid cancers.
As Chair of Forum and a Trustee of the British Society for Immunology (BSI) and a Council member of the International Union of Immunological Societies (IUIS) Ann is an advocate for Immunology to governments and other policy makers. Ann is also deputy chair of the BSI-NCRI alliance which brings together immunologists and oncologists who research, develop and use cancer immunotherapies to treat patients.
Stefan Glück, MD, PhD, FRCPC is medical oncologist and was V.P. Global Medical Affairs, at Celgene Corporation since October 2014 until December 2019. He oversaw oncology activities worldwide, as well as the Immuno-Oncology program in solid tumors and hematology. He also contributed to activities of Celgene around Early Assets. He previously served as a Sylvester Professor in the Department of Medicine at Miller School of Medicine, University of Miami, Florida until September 2014. From 2003–2008, he was the Clinical Director of the Braman Family Breast Cancer Institute, and from January 2009 - December 2010 Assistant Director of the Sylvester Comprehensive Cancer Center and Associate Chief, Division Hematology & Medical Oncology. He has been a PI of 37 clinical studies of breast cancer in Miami, as well as investigator in numerous scientific, translational projects. Before his move to Miami, Dr. Glück was Director of Southern Alberta Breast Cancer Program at the Tom Baker Cancer Center, a Professor in the departments of oncology, medicine, pharmacology & therapeutics at the University of Calgary, Alberta, Canada, and Deputy Head, Dept. of Oncology at the University of Calgary. He completed his medical studies at the Free University of West Berlin, Germany. The internship in Berlin was followed by residency in internal medicine and fellowship in hematology at the Heinrich Heine Universität in Düsseldorf, Germany, and a medical oncology & bone marrow transplant fellowship at the Princess Margaret Hospital, University of Toronto, Canada. Dr. Glück was presented the “America’s Top Oncologists” 2008 award from Consumers’ Research Council of America, as well as “Best Doctors in America” honor since 2006, and has annually earned that prestige every year to 2014. This award was warranted after less than 3 years of working in the United States.
He has authored or co-authored over 275 articles. In addition, Dr Glück has written or co-written several book chapters and numerous abstracts and has presented more than 500 papers at national and international meetings.
Dr Deonarain studied at Imperial College and Cambridge University where he carried out PhD research into protein engineering. From 1997-2011 Dr Deonarain was a Principle Investigator at Imperial College in Antibody Technology, which led to some novel technologies being developed commercially. Dr Deonarain now retains honorary links. He has published over 80 papers and patents in protein/antibody engineering/conjugates. In 2014, he co-founded Antikor Biopharma where he is the CSO leading a team of 15 to develop the next-generation of antibody-fragment based ADCs. Dr Deonarain is also Antikor’s CEO, driving the commercial development of Antikor’s OptiLink platform to develop FDC products for therapeutic applications
Dr Roghanian is a Lecturer (Assistant Professor) in cancer immunology and immunotherapy at the University of Southampton. Ali obtained his PhD from the University of Edinburgh, followed by several years of postdoctoral research at industry and academia. In 2015, Ali was a successful recipient of a Bloodwise Visiting Fellowship and spent two and half years at the Koch Institute for Integrative Cancer Research in MIT, USA, where he specialised in generating novel humanized mouse models of cancer. Ali was appointed as a lecturer in 2018 and currently leads his independent research group at the Centre for Cancer Immunology at Southampton. His research interests primarily focus on advancing cancer immunotherapy and the role of inhibitory receptors, expressed on immune cells and certain tumours. In particular he has been interested in exploring the ways in which reprogramming tumour-associated macrophages and myeloid-derived suppressor cells could overcome tumour microenvironment immunosuppression and enhance conventional cancer therapies.
Prof Sanz-Moreno received a degree in chemistry and a master's degree in biochemistry (University of Oviedo, Spain), followed by a PhD in chemical sciences (University of Cantabria). She joined the Institute of Cancer Research in London as a Marie Curie Intra-European Fellow to work with Prof Chris Marshall. In 2008, she received the Applied Biosystems and EACR 40th Anniversary Research Award. In 2011, Victoria started her independent group and received a CRUK Career Development Fellowship at King's College London. In 2015, she was highly commended as CRUK Communications and Brand Ambassador. In 2017, Victoria was awarded the BSCB Women in Cell Biology Early Career Award Medal. The same year, she received a CRUK Senior Fellowship and was badged Werth Trust Fellow. In 2018, Victoria joined Barts Cancer Institute (BCI-QMUL) as Professor of Cancer Cell Biology. In 2019, she received The Distinguished Alumnus Award from Colegio Inmaculada (Asturias) and Paper of the Year Award at BCI.
James Watson is the imaging and detection specialist for Thermo Fisher in London. Having worked in the commercial side of the life science industry for over 10 years he is passionate about bringing novel technologies and solutions to scientists in biomedical research.